Lung Cancer Serum Biomarker Discovery Using Label-Free Liquid Chromatography-Tandem Mass Spectrometry

Mass Spectrometry Platform, Cancer Biomarkers Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer (Impact Factor: 5.8). 02/2011; 6(4):725-34. DOI: 10.1097/JTO.0b013e31820c312e
Source: PubMed

ABSTRACT Lung cancer remains the leading cause of cancer-related death with poor survival due to the late stage at which lung cancer is typically diagnosed. Given the clinical burden from lung cancer and the relatively favorable survival associated with early-stage lung cancer, biomarkers for early detection of lung cancer are of important potential clinical benefit.
We performed a global lung cancer serum biomarker discovery study using liquid chromatography-tandem mass spectrometry in a set of pooled non-small cell lung cancer case sera and matched controls. Immunoaffinity subtraction was used to deplete the top most abundant serum proteins; the remaining serum proteins were subjected to trypsin digestion and analyzed in triplicate by liquid chromatography-tandem mass spectrometry. The tandem mass spectrum data were searched against the human proteome database, and the resultant spectral counting data were used to estimate the relative abundance of proteins across the case/control serum pools. The spectral counting-derived abundances of some candidate biomarker proteins were confirmed with multiple reaction monitoring mass spectrometry assays.
A list of 49 differentially abundant candidate proteins was compiled by applying a negative binomial regression model to the spectral counting data (p < 0.01). Functional analysis with Ingenuity Pathway Analysis tools showed significant enrichment of inflammatory response proteins, key molecules in cell-cell signaling and interaction network, and differential physiological responses for the two common non-small cell lung cancer subtypes.
We identified a set of candidate serum biomarkers with statistically significant differential abundance across the lung cancer case/control pools, which, when validated, could improve lung cancer early detection.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Considerable efforts have been undertaken to produce an effective screening method to reduce lung cancer mortality. Imaging tools such as low-dose computed tomography has shown an increase in the detection of early disease and a reduction in the rate of death. This screening modality has, however, several limitations, such as overdiagnosis and a high rate of false positives. Therefore, new screening methods, such as the use of circulating protein biomarkers, have emerged as an option that could complement imaging studies. In this review, current imaging techniques applied to lung cancer screening protocols are presented, as well as up-to-date status of circulating protein biomarker panels that may improve lung cancer diagnosis. Additionally, diverse statistical and artificial intelligence tools applied to the design and optimization of these panels are discussed along with the presentation of two commercially available blood tests recently developed to help detect lung cancer early.
    Future Oncology 06/2014; 10(8):1501-13. DOI:10.2217/fon.14.21 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is the leading cause of death worldwide. However, its early diagnosis and treatment improve survival. Due to the asymptomatic properties of almost all types of cancer, some patients are misdiagnosed or the disease is overlooked. Despite the availability of well-known diagnostic tools, such as computed tomography, a wide range of factors can limit a successful application of these techniques. The search for new alternative methods that would be able to diagnose cancer definitively has aroused scientific interest. Many coupled techniques have been employed for this purpose. Nevertheless, chromatographic platforms are considered to be among the most powerful diagnostic tools, which have enabled metabolic profiling, and, as a result, identified cancer biomarkers, which are essential in the treatment process. Rapid advances in technologies have made it possible to introduce new methods of treatment, based on individual predisposition.
    TrAC Trends in Analytical Chemistry 04/2014; 56. DOI:10.1016/j.trac.2013.12.007 · 6.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The recent introduction of multiple reaction monitoring to proteomics research has allowed many researchers to apply this technique to study human diseases. New methods: Here we combine subcellular fractionation of human autopsy brain with label-free multiple reaction monitoring to quantitatively analyse proteins in synapses. The protein enolase, from Streptococcus pyogenes serotype M6, which is sufficiently different from human proteins, was spiked into the sample mixture prior to trypsin digestion and used as an internal standard across samples. Results Three synaptic proteins and an internal standard analysed with four injections over four consecutive days gave consistent differences with a coefficient of variation of less than 4%. Consistent retention time was recorded across the replicates. Comparison with existing methods: Previously, multiple reaction monitoring analysis has been utilized to study human autopsy and animal tissues. Utilizing the synaptosomal fraction prior to analysis reduced sample complexity and allowed the enriched synaptic proteins to be quantitatively assessed in a highly reproducible manner, without the need for expensive fluorescent labels and synthetic peptides. Conclusion Protein expression can be measured with accuracy using label-free multiple reaction monitoring mass spectrometry in relatively complex human brain samples. Synaptic functions are critical for neuronal communication and function, and synapse dysfunction underlies many neurodegenerative diseases, including Alzheimer's disease. This method can be applied to study a range of brain disorders.
    Journal of neuroscience methods 04/2014; 227. DOI:10.1016/j.jneumeth.2014.02.016 · 1.96 Impact Factor

Full-text (2 Sources)

Available from
May 26, 2014